

**Original Article****Final Height and Endocrine Complications in Patients with  $\beta$ -Thalassemia Intermedia: Our Experience in Non-Transfused Versus Infrequently Transfused Patients and Correlations with Liver Iron Content**

Mohamed A. Yassin<sup>1</sup>, Ashraf T. Soliman<sup>2</sup>, Vincenzo De Sanctis<sup>3</sup>, Khadra S. Yassin<sup>1</sup> and Mohammad AJ. Abdulla<sup>1</sup>.

<sup>1</sup> Hematology Section, National Center for Cancer Care and Research, Hamad Medical Corporation, (HMC), Doha, Qatar.

<sup>2</sup> Departments of Pediatrics, Hamad Medical Center, Doha, Qatar.

<sup>3</sup> Pediatric and Adolescent Outpatient Clinic, Quisisana Hospital, Ferrara, Italy.

**Competing interests:** The authors have declared that no competing interests exist.

**Abstract. Background:**  $\beta$ -thalassemia intermedia (TI) spans a wide spectrum of severity and carries higher morbidity than previously recognized, including extramedullary hematopoiesis, leg ulcers, gallstones, thrombosis, secondary heart failure, pulmonary hypertension, skeletal deformity, growth retardation and endocrine abnormalities, such as diabetes mellitus, hypothyroidism, osteoporosis, and hypogonadism.

**Objectives:** To evaluate the final height and the endocrine complications encountered in young adult patients with TI followed at Hematology Section, Doha (Qatar) in relation to liver iron content in non-transfused versus infrequently transfused TI patients.

**Patients and Methods:** This retrospective cohort study was performed on 28 young adults with TI who were randomly selected from the Hematology Clinic of the Hematology Section, National Centre for Cancer Care and Research, Hamad Medical Corporation of Doha (Qatar).

Eligibility criteria for this retrospective analysis included TI patients diagnosed by complete blood count, hemoglobin electrophoresis and young adult age ( $\geq 18$  years).

Group 1 included nine patients who did not receive any blood transfusion, and Group 2 included 19 patients who infrequently received blood transfusions.

Data recorded from charts included demographic characteristics (gender, date of birth, ethnicity), disease and treatment characteristics (e.g., transfusion frequency, history of chelation therapy, and splenectomy), auxological and pubertal data [growth percentiles and pubertal stages, and body mass index (BMI)], laboratory data and target organ complications (including endocrinopathies and liver disease). Iron overload was assessed by direct (liver iron content; LIC) and indirect methods (SF), and bone mass index (BMA) by dual-energy X-ray absorptiometry (DXA).

**Results:** Short stature [Final Height (Ht) SDS  $< -2$ ] occurred in 25% of patients with no difference between the two groups of patients. Insulin growth factor 1 (IGF-1) SDS was low in 35.7 % of patients with no statistical difference among the two groups. Impaired fasting blood glucose occurred in 17.8% of patients, diabetes mellitus in 25% and hypogonadotropic hypogonadism in 10.7% of them. Morning cortisol was low in one patient. No thyroid or hypoparathyroid abnormalities were detected in any patient. Liver iron content (LIC)  $> 15$  mg/g dry weight and SF  $> 2,000$  ng/mL were detected in 75% of the patients. The values resulted significantly higher in the transfused group (Group 2). High liver enzyme level (ALT) was detected in 42.8 % of patients, and the values were significantly higher in the transfused group (Group 2). Total and fetal Hb was significantly higher in group 1 versus group 2. Osteopenia was diagnosed in 14.3% of patients. Females had significantly better final height SDS, higher IGF-1 SDS, lower LIC and fasting blood glucose level compared to males. Significant correlations were

found between Ht-SDS and IGF-1 SDS; LIC and SF, level; ALT and LIC, SF levels. Total and fetal Hb did not correlate significantly with Ht-SDS or IGF-1 level.

**Conclusions:** A significant number of TI patients have high LIC, short stature and endocrine disorders. Patients who require occasional transfusions have more liver iron overload and higher hepatic dysfunction. Females appear to attain a better final adult height and have higher IGF1-SDS versus males. Our data emphasize the need for long term surveillance for identification of organ-specific risk factors and early disease manifestations. We also recommend close monitoring of endocrine and other complications, according to the international guidelines.

**Keywords:** Thalassemia intermedia; Gender; Growth; Endocrine complications; IGF-1; Iron overload; Liver iron concentration; Serum ferritin.

**Citation:** Yassin M.A., Soliman A.T., De Sanctis V., Yassin K.S., Abdulla M.A.J. Final height and endocrine complications in patients with  $\beta$ -thalassemia intermedia: our experience in non-transfused versus infrequently transfused patients and correlations with liver iron content. *Mediterr J Hematol Infect Dis* 2019, 11(1): e2019026, DOI: <http://dx.doi.org/10.4084/MJHID.2019.026>

**Published:** May 1, 2019

**Received:** January 8, 2018

**Accepted:** April 6, 2018

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<https://creativecommons.org/licenses/by-nc/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Correspondence to: Mohamed A Yassin, MD. Consultant Hematologist, Hematology Section, National Center for Cancer Care and Research, Hamad Medical Corporation, Doha (Qatar). E-mail: [Yassinmoha@gmail.com](mailto:Yassinmoha@gmail.com)

**Introduction.** According to the WHO, the carrier rate of  $\beta$ -thalassemia is around 1.5% of the world population.  $\beta$ -thalassemia intermedia (TI) defines a group of patients whose anemia is not so severe to necessitate regular transfusions but are at significant risk of iron accumulation from underlying disease-related mechanisms distinct from transfusional iron overload. TI is characterized by significant genetic and clinical heterogeneity.<sup>1,2</sup>

Three mechanisms are responsible for having a milder phenotype of thalassemia. First, is the inheritance of a mild or silent beta-chain mutation. The second is the coinheritance of  $\alpha$ -thalassemia. The third is the hereditary persistence of HbF,  $\delta\beta$ -thalassemia, and G $\gamma$  XMN1 polymorphism.<sup>3</sup> Due to imbalances in  $\alpha$ - and  $\beta$ -globin chains, globin tetramers are unstable resulting in precipitation and degradation. This process releases free iron and leads to the formation of reactive oxygen species (ROS), causing membrane damage and premature cell death in bone marrow (ineffective erythropoiesis) or peripheral circulation.<sup>3-5</sup>

Clinically, they present in later childhood or even in early adulthood with a mild to moderate anemia, with a hemoglobin (Hb) level ranging between 7 and 10 g/dL, that only requires occasional or short-course of regular transfusions in certain clinical settings (e.g., in the course of infections or pregnancy).<sup>1,2</sup> More severely affected patients present younger, between 2 and 6 years of age, and require transfusions for normal and sustained growth.

The triad of chronic anemia, ineffective erythropoiesis, and iron overload characterizes TI and eventually culminate in the clinical sequelae that we see in these patients, including extramedullary hematopoiesis, leg ulcers, gallstones, thrombosis, skeletal deformities, osteoporosis, heart failure,

pulmonary hypertension, and endocrine complications (such as diabetes mellitus, hypothyroidism, and hypogonadism).<sup>4-8</sup> The complications are associated with the severity of anemia and iron overload, splenectomy, older age, the rate of ineffective erythropoiesis, and low fetal Hb levels.<sup>8,9</sup>

Conventional treatment consists of transfusions, iron chelation, splenectomy, Hb F-inducing agents, supportive therapies, and psychological support. However, management of these patients is particularly challenging for clinicians because they can present with a wide variety of complications which can vary in severity. Therefore, the treatment of TI must be individualized and tailored to the patient's clinical scenario.

Qatar is a peninsula bordering the Arabian Gulf and Saudi Arabia. The country's population has been roughly split with 20% native Qatari, mostly tribal, and 25% other Arabs from Egypt, Syria, Iraq, Lebanon, Yemen, Palestine, and Jordan. The rest of the population (55%) consists of expatriate workers from the East and the West.<sup>10</sup>

The frequency of  $\beta$ -thalassemia heterozygotes is estimated to be 2-3%. Al-Obaidli et al.<sup>11</sup> analyzed the molecular basis of  $\beta$ -thalassemia in Qatar. They found the most common mutant alleles were IVS-1-5 (G>C) and codon 8/9 (+G), representing 35.4% and 26.1% of the total, respectively. Most of these two mutations are homozygous, probably because of the high rate of consanguinity. Recently, a novel  $\beta$ -thalassemia deletional variant allele in an ethnic Qatari patient was reported.<sup>11</sup> The deletion spans exon 1, the entire intron 1 and the first two bases of exon 2 causing a frameshift and the premature appearance of a stop codon. The presence of this novel deletional allele in a compound heterozygous state with a non-deletional allele is

alarming in a diagnostic setting, especially in the absence of family studies. The frequencies of three other common mutant alleles, IVS-2-1 (G>A), 25bp deletion and IVS-1-110 (G>A) are higher in surrounding locations, such as Southern Iran, Kuwait, eastern Saudi Arabia, and Bahrain.<sup>12</sup>

We report for the first time the endocrine complications encountered in young adult patients with TI followed at Hematology Section, Doha (Qatar) and we shed further light on their final height and hormonal changes in relation to liver iron content in non-transfused versus infrequently transfused TI patients.

**Patients and Methods.** Patients with  $\beta$ -thalassemia and sickle cell disease are treated comprehensively in Hamad Medical Corporation (HMC) where the Pediatric Hematology Department takes care of these patients up to the age of 14 years. After the age of 14 years, patients are treated in the Hematology Sections of the National Centre for Cancer Care and Research. The center is following the Thalassemia International Federation (TIF) guidelines for treatment of patients with Hemoglobinopathies. In addition, our health care system in Qatar provides standard high-quality care for these patients. The center is accredited by a joint International Commission, and the laboratories are accredited by American College of Pathologist.

This retrospective cohort study was performed on twenty-eight young adults (20 males and 8 females) with TI who were randomly selected from the Hematology Clinic of the National Centre for Cancer Care and Research (NCCCR) of Doha (Qatar). Two patients had splenectomy and one developed extramedullary mass with spinal compression. None was hepatitis B or C positive.

Eligibility criteria for this retrospective analysis included TI patients diagnosed by complete blood count, hemoglobin electrophoresis and young adult age ( $\geq 18$  years).

Data recorded from medical charts included the demographic characteristics (gender, date of birth, ethnicity), disease and treatment characteristics (e.g., transfusion frequency, history of chelation therapy, and splenectomy), auxological and pubertal data [growth percentiles and pubertal stages, and body mass index (BMI)]. Laboratory data included the Hb level, mean corpuscular volume (MCV), indirect bilirubin, and target organ complications (including endocrinopathies and liver disease).

Short stature was defined as patient height  $< 2$  standard deviations below the mean for age, gender, and ethnicity. Short stature was evaluated by assessment of patient height and plotted on international (WHO) adjusted growth charts.<sup>11</sup> Body mass index (BMI) was calculated with the following formula: weight in Kg/ height in m<sup>2</sup>.<sup>13</sup>

Hypogonadism was suspected by the absence of breast development or secondary amenorrhea and by the absence or arrest of testicular enlargement, measured with Prader's orchidometer.<sup>14</sup> Male and female patients with suspected hypogonadism were evaluated for pituitary-gonadal axis integrity.<sup>3,15</sup> Low blood testosterone levels (in males) or 17 $\beta$ estradiol (in females) associated with low pituitary gonadotropin levels (LH and FSH) indicated a diagnosis of hypogonadotropic hypogonadism (HH). Hyperprolactinemia was defined as a basal level higher than the locally derived normal assay reference range.

Primary hypothyroidism was diagnosed in the presence of low serum free thyroxine (FT4) and elevated serum thyroid stimulating hormone (TSH) concentration<sup>10</sup> and central hypothyroidism was diagnosed when FT4 was low, and TSH was low or inappropriately normal for the FT4 level.<sup>13,15</sup> The criteria for the diagnosis of hypoparathyroidism were: low parathormone (PTH) level with low total and ionized serum calcium, high serum phosphate, normal serum magnesium, and alkaline phosphatase levels.<sup>10</sup>

The criteria for diabetes mellitus were based according to the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (ADA), 1998 World Health Organization (WHO) consultation criteria, and 1985 WHO criteria.<sup>13</sup> Impaired fasting blood glucose (FBG) was diagnosed in the presence of fasting glucose  $\geq 5.6$  mmol/L but  $< 7.0$  mmol/L and diabetes mellitus (DM) in the presence of fasting glucose  $\geq 7.0$  mmol/L or two-hour postprandial glucose  $\geq 11.1$  mmol/L.<sup>16</sup>

Hypoadrenalism was suspected in the presence of basal morning cortisol level  $< 3.5$   $\mu$ g/dl (98 nmol/liter) or less.<sup>17</sup>

Other laboratory investigations included: alanine transferase (ALT), aspartate transferase (AST), and insulin-like growth factor (IGF-1).

Plasma total IGF-1 was measured by a chemiluminescent immunometric assay (CLIA) method (Nichols Institute Diagnostics, San Juan, CA). For ethical reasons, we used as a reference for normal the IGF-1 values determined in a large population of healthy subjects, reported in the literature<sup>18</sup> using the same automated chemiluminescence immunoassay system (CLIA). A serum IGF-1 level  $< -2$  SDS was considered a deficiency. Other hormonal parameters were determined using commercially available automated immunoassays.

Patients were divided into two groups based on their transfusional history: Group 1 included 19 patients (7 females and 12 males) who did not receive any blood transfusion and group 2 included 9 patients (2 females and 7 males) who infrequently received blood transfusion; no more than five transfusions in the last 3 years). None had received HbF induction therapy.

Iron overload was assessed by indirect (SF) and direct methods (liver iron content; LIC).

Electrochemiluminescence immunoassays measured SF level. The manufacturer's normal reference range values for SF were 30–350 ng/L, in males, and 15–150 ng/mL in females. Iron status was classified as mild (serum ferritin < 1,000 ng/mL), moderate (serum ferritin >1,000 ng/mL and < 2,000 ng/mL) or severe (serum ferritin >2,000 ng/mL).<sup>19</sup>

Liver iron content (LIC) was measured by FerriScan® and values were expressed in mg Fe/g weight. Four classes of LIC have been reported in thalassemic patients: Class 1 = normal LIC < 3 mg Fe/g dry liver, Class 2 = mild overload LIC 3–7 mg Fe/g dry weight, Class 3 = moderate LIC overload 7–15 mg Fe/g dry weight, and Class 4 = severe LIC overload ≥15 mg Fe/g dry weight.<sup>19-21</sup>

Patients with serum ferritin > 2,000 ng/mL were treated with subcutaneous daily desferrioxamine during childhood. All patients were shifted, 7 years ago, to oral chelation therapy with deferasirox (20 mg/Kg/body/d), with dose escalations up to 30 mg/kg/d. In the last year, deferasirox (DFX) was shifted to the new tablet DFX formulation (Jadenu® :14 mg/kg/d with dose escalations up to 21 mg /kg/d).

The assessment of bone mineral density (BMD) was measured by dual-energy

X-ray absorptiometry (DXA). BMD of the lumbar spine (L1–L4) and right femoral neck were measured. The BMD values were expressed as mean values (g/cm<sup>2</sup>). Z-score, which is the number of SD above or below the average of age- and sex-matched control subjects' BMD, was calculated.<sup>17</sup> Based on the World Health Organisation definition, a Z-score of less than – 2.5 SDS below the mean in relation to the patient's age was defined as osteoporosis, and between –1.0 and – 2.5 SDS as osteopenia.<sup>22</sup>

Ethical approval for the study was obtained by the IRB of the Medical Research Center at Hamad Medical Corporation. All procedures were carried out with the adequate understanding and consent of patients.

The Kolmogorov-Smirnov (K-S) test and PP plot were used to test for normality of the data. Quantitative data between the two independent groups were analyzed using unpaired 't' test or Mann Whitney U test as appropriate. The relationship between two

quantitative variables was examined using Pearson's correlation coefficients. We used. All p values presented were two-tailed, and p values <0.05 was considered as statistically significant. All statistical analyses were done using Excel statistical packages 2010 software.

**Results.** Patients' characteristics and biochemical parameters in 28 young adult patients with β-thalassemia intermedia are reported in **table 1**.

A short final stature (Ht-SDS < -2) occurred in 25% of patients and in 35.7 %. The IGF-1

SDS level was low, with no statistical difference among the two groups. FBG occurred in 17.8% of patients, DM in 25% and acquired hypogonadotropic hypogonadism in 10.7% of them (2 patients with hypogonadotropic secondary amenorrhea and one male patient with acquired HH). The two females had secondary amenorrhea after a complete spontaneous pubertal development. Morning basal cortisol was low in one patient in the non-transfusion group. No thyroid or parathyroid abnormality was detected in any patient (**Table 2**).

Increased ALT levels (> 40 U/L) were detected in 42.8 % of patients. The levels resulted significantly higher in the transfused group (73.3±34.3 vs. 42.2±32.1 in NTD of Group 1). Total Hb and fetal Hb were significantly higher in Group 1 (8.2 ± 2.8 g/dL and 2.8 ± 1.6 %, respectively) versus Group 2 (7.0 ± 0.4 g/dL and 1.2 ± 0.42 g/dL, respectively) (**Tables 1 and 2**).

SF was > 2,000 ng/mL in 12/19 (63%) and LIC > 15 mg/g liver dry weight in 12/19 (63.1%) of patients who did not receive blood transfusion (Group 1) and in 100 % of patients who received occasional blood transfusions (Group 2). Liver iron content > 15 mg/g dry weight and serum ferritin level > 2, 000 ng/mL were detected in 75% of the patients. Four patients with SF concentration < 1,000 ng/mL had a high LIC >15 mg/g dry weight. Although the mean SF level in males was comparable to the mean SF level in females, LIC of females was significantly lower.

Comparison of males versus females with TI showed that females had significantly better adult final Ht-SDS (- 0.45 ± 1.06 vs. -1.80 ± 0.88; p: 0.0001), higher IGF-1 SDS (-1.09 ± 1.73 vs. -1.80 ± 1.71;p: 0.01), lower LIC ( 24.4± 8.5 vs.32.3 ± 12.5 mg Fe/g

**Table 1.** Patients' characteristics and biochemical parameters in 28 patients with β-thalassemia intermedia

Groups 1 and 2	Age (years)	Fetal Hb (%)	Hb (g/dL)	Height-SDS	SF (ng/mL)	LIC (mg Fe/g dry weight)	AST (U/L)	ALT (U/L)	ALP (U/L)
NTD (19)	24.7±7.8	2.9±1.6*	8.2±0.8	1.5±1.2	2,874±732	23.5±9.5	33.7±14.7	42.2±32.1	133.1±92.3
OTD (9)	24.3± 7.2	1.2±0.4	7.0±0.3	1.6±1.0	7,518±618*	40.5±10.7 *	48.2±15.1	73.3±34.3*	118.3±46.6

**Legend= Groups:** NTD: TI patients not receiving blood transfusions; OTD: TI patients infrequently receiving blood transfusions; **SF:** serum ferritin; **LIC:** liver iron concentration; **ALT:** alanine transferase; **AST:** aspartate transferase (**AST**); **ALP:** alkaline phosphatase; (\*p: < 0.05, non-paired t test).

**Table 2.** Final adult height (Ht-SDS), endocrine complications, biochemical parameters and bone densitometry in 28 patients with  $\beta$ -thalassemia intermedia.

Variables and endocrine complications	Total N = 28	Group 1 N = 19	Group 2 N = 9	P value (Group 1 vs. Group 2)
Ht-SDS < -2	7/28	4/19	3/9	0.45
IGF-1 SDS < -2	10/28	5/19	5/9	0.13
Hypoparathyroidism	0/28	0/19	0/9	NA
Hypothyroidism	0/28	0/19	0/9	NA
Low basal cortisol	1/28	1/19	0/9	0.48
Impaired FBG (mmol/L)	5/28 --	2/19 5.5 $\pm$ 1.2	3/9 7.5 $\pm$ 2.3	0.14 <0.05
Diabetes mellitus	7/28	3/19	4/9	0.1
Hypogonadism	3/28	1/19	2/9	0.17
Serum ferritin > 2,000 ng/mL	21/28	12/19	9/9	0.035
High ALT (> 40 U/L)	12/28	5/19	7/9	0.01
LIC > 15 mg Fe/g dry weight	21/28	12/19	9/9	0.035
Hb < 8 g/dL	16/28	7/19	9/9	0.001
Osteopenia (DXA scan)	4/28	3/19	1/9	0.74

**Legend:** NTD: TI patients not receiving blood transfusions; OTD: TI patients infrequently receiving blood transfusions; Ht: standing height; NA: not applicable; IGF-1: insulin growth factor 1; FBG: fasting blood glucose; ALT: alanine transferase; LIC: liver iron concentration; Hb: hemoglobin level; DXA: dual-energy X-ray absorptiometry (p value for t-test between two percents).

**Table 3.** Correlations (r values) between anthropometric and biochemical variables in patients with  $\beta$ -thalassemia intermedia.

	Ht-SDS	BMI	AST	ALT	FBG	LIC	Serum ferritin	FT4	IGF-1 SDS
Ht-SDS	1.00								
BMI	0.03	1.00							
AST	0.01	0.26	1.00						
ALT	-0.10	0.17	0.72	1.00					
FBG	-0.01	0.04	0.20	0.20	1.00				
LIC	0.11	-0.21	0.52	0.43	0.15	1.00			
Serum ferritin	0.00	-0.06	0.36*	0.35*	0.21	0.47*	1.00		
FT4	0.05	0.08	-0.06	0.06	0.10	-0.30	-0.18	1.00	
IGF-1 SDS	0.65**	0.35*	-0.04	0.17	-0.15	-0.19	-0.03	0.42	1.00

**Legend:** Ht: standing height; BMD: body mass index; AST: aspartate transferase (AST); FBG: fasting blood glucose; LIC: liver iron concentration; FT4: free thyroxine; IGF-1: insulin growth factor 1; \*p < 0.01, \*\*p < 0.001. Strength of correlation (r) - 0.70 = A strong negative linear relationship, - 0.50 = A moderate negative relationship, - 0.30 = A weak negative linear relationship, 0 = No linear relationship, + 0.30 = A weak positive linear relationship, + 0.50 = A moderate positive relationship and + 0.70 = A strong positive linear relationship).


dry weight; p: 0.03), ALP (85.5  $\pm$  20.9 vs. 144.6  $\pm$  84.5 U/L; p:0.04, Normal values: 40-129 U/L) and FBG (5.7  $\pm$  2.2 vs. 7.1  $\pm$  4.4 mmol/L; p: 0.04) compared to males.

ALT was not significantly lower in females versus males (43.1  $\pm$  16.7 vs. 55.1  $\pm$  38.7 U/L; p: 0.6. Normal values: < 40 U/L).


LIC was correlated significantly with serum ferritin level (Figure 1). Ht-SDS was correlated significantly with IGF-1 SDS (Figure 2) and BMI. ALT concentrations were correlated significantly with LIC and SF level. Total Hb and fetal Hb did not correlate

significantly with Ht-SDS or IGF-1 level. Osteopenia was diagnosed by DXA scan in 14.3% of patients (Table 2).

**Discussion.**  $\beta$ -thalassaemia intermedia (TI) is an inherited genetic disorder that affects haemoglobin chain synthesis, leading to ineffective erythropoiesis and anemia. Despite absent or infrequent blood transfusions, patients with TI are at risk of iron overload mainly because of increased iron uptake from the gastrointestinal tract, because of ineffective erythropoiesis, accompanied by anemia and hypoxia.<sup>20</sup>



**Figure 1.** Correlation between liver iron concentration (LIC) and serum ferritin ( $r = 0.47$ ;  $P: 0.01$ ).



**Figure 2.** Correlation between standing height - SDS (Ht-SDS) and insulin growth factor- 1 SDS (IGF1SDS) ( $r = 0.65$ ;  $P: < 0.001$ ).

In these patients, iron absorption is 3–10 times normal, which is 17–89 % compared to  $14.8 \pm 9.5$  % in normal subjects and increases after splenectomy.<sup>23-25</sup> This iron burden promotes oxidative damage in a variety of organs, inducing a variety of endocrine and end-organ dysfunction.

When comparing our patient's data with data published by other groups from Iran, Lebanon, and Italy, we clinically noticed that minor  $\beta$ - thalassemia and mild phenotype of the disease is more common in Qatar compared to others gulf countries.<sup>10,12</sup>

Our patients with and without occasional transfusion had markedly high SF level and LIC. A significant correlation between SF and LIC was observed in our patients as reported in another study.<sup>26</sup> Four patients in spite of an SF concentration not particularly elevated ( $< 1,000$  ng/mL) had a high LIC  $> 15$  mg/g dry weight, thus remaining at risk of being denied iron chelation therapy although they need it, and exposing patients to morbidity and mortality risks associated to iron overload. Vascular, endocrine, and bone morbidity in TI are significantly associated with SF  $> 800$  ng/mL and LIC  $> 6-7$  mg Fe/g dry weight.<sup>27-30</sup>

The main aim of our retrospective study was to evaluate the final height and the endocrine complications in relation to their iron status and degree of anemia and to compare LIC and endocrine status in patients on occasional transfusion (Group 2) versus those who did not receive a blood transfusion (Group 1). Twenty-five percent of patients had short stature (Ht-SDS  $< -2$ ), and 35.7% had low IGF-I ( $< -2$ SD), with no statistical difference among the two groups. Females attained a better final height and showed a higher IGF1- SDS versus males. Impaired fasting blood glucose occurred in 17.8%, DM in 25% and hypogonadotropic hypogonadism in 10.7% of them. Morning cortisol was low in one patient. No thyroid or parathyroid abnormalities were detected in our study.

Karamifar et al.<sup>31</sup> investigated 93 patients with TI (40 males, 53 females), aged 11-40 years (mean 19.4 yr). Short stature (height  $< 3^{\text{rd}}$  percentile) was documented in 47% and growth hormone deficiency in 31% of their patients. A lower incidence of final short stature (7%) was reported by De Sanctis et al.<sup>6</sup> in 50 patients (21 males, 29 females) with TI (aged 15-46 years; mean age 28.7 yr), with raised SF levels (mean 1,540 ng/mL). Mean hemoglobin concentration was 8.1 g/dL. Half of them had had more than 50 transfusions in their life and had received irregular intramuscular or subcutaneous chelation therapy with desferrioxamine.

The difference in the prevalence of short stature may be due to several factors: gender, low fetal hemoglobin level,<sup>32</sup> severity of anemia,<sup>30-33</sup> treatment of iron overload and compliance to medical care.<sup>4,6,8</sup>

The Ht-SDS of our patients was correlated significantly with IGF-1 level, suggesting that IGF-1 deficiency may play a key role in growth retardation of these patients. The Ht-SDS was not correlated with SF, LIC, Hb F or total Hb levels. However, the lower LIC levels found in our female patients can explain their higher IGF1-SDS and better final adult Ht-SDS as well as lower ALT concentrations compared to males. The lower LIC levels found in our female patients can explain their higher IGF1-SDS and better final adult Ht-SDS as well as lower ALT concentrations compared to males.

A low Hb has been associated with low IGF-1 levels and slow growth in many disorders including iron deficiency anemia and thalassemia major.<sup>33-36</sup> Correction of the anemia was associated with increasing IGF-1 secretion and acceleration of growth in these disorders.<sup>31</sup>

Thus, the adverse effects of iron overload, the severity of anemia and a defective secretion of growth hormone GH-IGF-1 axis could explain the short stature and the reduced synthesis low IGF-1 in patients with TI. Additional factors include hepatic impairment, other associated endocrine complications, and zinc deficiency.<sup>36,37</sup>

Our patients had a high prevalence of impaired FBG (17.8%) and DM (25%).

Patients on occasional blood transfusion who had higher iron overload (SF and LIC) had a higher FBG compared to the non-transfused group.

In a study by Flatau et al.<sup>38</sup> abnormal glucose tolerance was detected in two out of 4 patients. In these two patients, the SF levels were more than 20 times the average value. Abnormal glucose tolerance test (OGTT) was found in 24% of patients in De Sanctis et al. study.<sup>6</sup> These patients had a higher serum SF level and a lower Hb level than those with normal OGTT. A diagnosis of DM was reported by Karimi et al.<sup>39</sup> in 11% of 721 TI patients from twelve comprehensive thalassemia centers.

Although our patient did not have any thyroid dysfunction or calcium homeostasis abnormality, primary hypothyroidism was detected in 5.7% of patients reported by De Sanctis et al.<sup>6</sup> Compensated hypothyroidism and primary hypothyroidism was documented respectively in 19% and 2% of patients reported by Karamifar et al.,<sup>31</sup> and central hypothyroidism in 8.3% of 721 TI patients.<sup>39</sup>

Thus, different studies have revealed that several changes in thyroid hormone concentrations may occur with a broad spectrum of severity from compensated to overt hypothyroidism. Central hypothyroidism, considered an uncommon clinical entity in the past, is an emerging endocrine complication due to inadequate stimulation of a normal thyroid gland by TSH (low FT4 and a low or “inappropriately normal” TSH).

HH occurred in 10.7 % of our patients. Prevalence of hypogonadism ranging from 4.2 % to 16 % has been reported by different authors.<sup>6,31,39,40</sup> The detailed description of this complication, in the current literature, is quite scanty. De Sanctis et al.<sup>6</sup> found a delayed puberty in 36% of patients, primary amenorrhea in 4% and secondary amenorrhea in 4 out of 50 TI patients (8%). Two adult males (aged 19 and 36 years) had HH (4%).<sup>6</sup> A poor response to Gn-RH stimulation test, found in three females and in both males tested, suggested that pituitary dysfunction was wholly or partially responsible for hypogonadism. The gonadal function was normal in all patients studied. The appearance of endocrine complications was not necessarily related to the degree of iron overload as evaluated by SF.<sup>6</sup>

However, lack of concordance of SF concentrations and different endocrine dysfunctions can be explained by the fact that serum ferritin levels increase linearly with the transfusion load up to 100 units of transfused blood, but after that there is no simple relationship.<sup>31,39,40</sup> Moreover, there is no direct linear relationship between the amount of iron accumulated and organ dysfunctions.<sup>41</sup> Furthermore, it is possible that endocrine glands are more sensitive to iron toxicity compared to other organs and that even small amounts

of it accumulated in the first few years of life produce damage that cannot be reversed.

Cut-offs of < 300 ng/mL for the absence of iron overload and > 800 ng/mL for the presence of clinically significant iron overload in TI have been suggested.<sup>38</sup> However, recent re-evaluation found that a considerable number of patients with SF levels between 300 and 800 ng/mL to have iron overload requiring management.<sup>42,43</sup> Iron chelation therapy and hydroxyurea therapy have been associated with a lower frequency of endocrine complications.<sup>9</sup> One postulated mechanism of action of hemoglobin F inducers is based on reducing the imbalance between  $\alpha$ -globin chains and non- $\alpha$  chains.

DFX, an oral chelator with a once-daily dosage, was developed to provide day-long chelation coverage with a suitable safety and efficacy profile. A recent study, called THALASSA (Assessment of Exjade® in Non-Transfusion-Dependent Thalassemia), on 166 patients with TI (>10 years of age with a LIC  $\geq$  5 mg Fe/g dry weight, and SF level of at least 300 ng/mL) showed the efficacy of DFX at starting doses of 5 and 10 mg/kg/d, with dose escalations up to 20 mg/kg/d in patients with high levels of iron overload.<sup>44</sup>

However, despite the availability of long term chelation therapy including oral agents for 7 years, in our patients iron overload remains a serious problem because of poor compliance to treatment. The uncomfortable side effects of therapy can have a negative impact on daily activities and well-being, which may affect adherence.<sup>45</sup> A new tablet DFX formulation (Jadenu®) has been recently developed in an attempt to overcome tolerability issues and to improve the patients' compliance.<sup>46</sup>

These observations suggest that doctors taking care of patients with thalassemias should be aware of the importance of monitoring iron load and should implement strategies for improving compliance with the treatment.

Bone abnormalities in TI are quite frequent and range from a decrease in the bone mineral density (BMD) and consequent osteoporosis to spinal cord compression and increased risk of fractures.<sup>43</sup> Osteopenia occurred in 14.3 % of our young adults with TI. Other authors have reported a prevalence of bone disease in 53/70 (76%) patients, osteoporosis in 26/53 (49%), and osteopenia in 27/53 (51%).<sup>43</sup> Relatively lower prevalence of osteopenia in our patients may be due to their young age, with high activity, regular intake of vitamin D, calcium and dairy products.

Most of our patients with TI had decreased levels of IGF-1 that usually plays an essential role in the bone remodeling cycle that stimulates osteoclasts and the differentiation and proliferation of osteoblasts. An increased level of the receptor activator of nuclear factor KB ligand (RANKL) leads to decreased bone

thickness followed by bony deformities, osteopenia, and ultimately fractures.<sup>40</sup> However, several other factors including bone marrow expansion, ineffective erythropoiesis, vitamin D deficiency, genetic factors, and reduced physical activity may contribute to lower bone mineral accretion in these patients.<sup>44</sup>

The most recent guidelines by the Thalassemia International Federation (TIF) recommend that all patients >10 years of age be screened by yearly assessment of lumbar spine, femoral neck, and distal ulna BMD by DXA.<sup>47,48</sup>

**Conclusions.** Although many TI patients do not present serious health problem and they generally reach adult age without or with a little requirement of blood transfusion, growth impairment, and endocrine disturbances have been reported with variable prevalence among these patients. The degree of iron overload and the effect of anemia and variation in iron chelation therapy prescription could explain the variation in the prevalence of endocrine complications reported in the literature.

In TI the pattern of iron overload is preferentially hepatic, and it develops gradually throughout life,

manifesting as early as ten years of age. Our patients who received occasional transfusions (Group 2) had higher ALT and LIC versus those who did not receive transfusions (Group 1). LIC correlated significantly with ALT level stating that liver impairment increase with the iron overload.

Spot ferritin measurements may underestimate the burden of iron overload and subsequently delay the iron chelation therapy but its monthly measurement could have some value in countries where LIC assessment is not available. LIC is the most reliable and noninvasive gold standard method to assess iron overload.

Finally, our data also emphasize the need for long term surveillance for identification of organ-specific risk factors, early diagnosis, and treatment of growth and endocrine complications. We also recommend close monitoring of endocrine and other complications, according to the international guidelines.

**Acknowledgments.** The Authors wish to thank the Qatar Library for supporting the publication of our research.

## References:

1. Taher AT, Temraz S, Cappellini MD. Deferasirox for the treatment of iron overload in non-transfusion-dependent thalassemia. *Expert Rev Hematol.* 2013;6:495-509. <https://doi.org/10.1586/17474086.2013.827411> PMID:24083402
2. Cappellini MD, Musallam Khaled M, Taher Ali T. Insight onto the pathophysiology and clinical complications of thalassemia intermedia. *Hemoglobin.* 2009;33:S145-159. <https://doi.org/10.3109/03630260903351528> PMID:20001620
3. Galanello R, Cao A. Relationship between genotype and phenotype. *Thalassemia intermedia.* *Ann NY Acad Sci.* 1998; 850: 325-333. <https://doi.org/10.1111/j.1749-6632.1998.tb10489.x> PMID:9668554
4. Karimi M, Cohan N, De Sanctis V, Mallat NS, Taher A. Guidelines for diagnosis and management of Beta-thalassemia intermedia. *Pediatr Hematol Oncol.* 2014;31:583-596. <https://doi.org/10.3109/08880018.2014.937884> PMID:25247665
5. Taher A, Hershko C, Cappellini MD. Iron overload in thalassaemia intermedia: Reassessment of iron chelation strategies. *Br J Haematol.* 2009; 147: 634-640. <https://doi.org/10.1111/j.1365-2141.2009.07848.x> PMID:19681884
6. De Sanctis V, Tangerini A, Testa MR, Lauriola AL, Gamberini MR, Cavallini AR, Rigolin F. Final height and endocrine function in thalassaemia intermedia. *J Pediatr Endocrinol Metab.* 1998;11 (Suppl 3):965-971. PMID:10091174
7. De Sanctis V, Soliman AT, Canatan D, Elsedfy H, Karimi M, Daar S, Rimawi H, Christou S, Skordis N, Tzoulis P, Sobti P, Kakkar S, Kilinc Y, Khater D, Alyaarubi SA, Kaleva V, Lum SH, Yassin MA, Saki F, Obiedat M, Anastasi S, Galati MC, Raiola G, Campisi S, Soliman N, Elshinawy M, Jaouni SA, Di Maio S, Wali Y, Elhakim IZ, Kattamis C. An ICET- A survey on Hypoparathyroidism in Patients with Thalassaemia Major and Intermedia: A preliminary report. *Acta Biomed.* 2018;88:435-444. PMID:29350657
8. Inati A, Noureldine MA, Mansour A, Abbas HA. Endocrine and bone complications in  $\beta$ -thalassaemia intermedia: current understanding and treatment. *Biomed Res Int.* 2015 <https://doi.org/10.1155/2015/813098> PMID:25834825 PMCid:PMC4365366
9. Taher AT., Musallam KM., Karimi M, El-Beshlawy A, Belhoul K, Daar S, Saned MS, El-Chafic AH, Fasulo MR, Cappellini MD. Overview on practices in thalassaemia intermedia management aiming for lowering complication rates across a region of endemicity: the optimal care study. *Blood.* 2010;115:1886-1892. <https://doi.org/10.1182/blood-2009-09-243154> PMID:20032507
10. De Sanctis V, Kattamis C, Canatan D, Soliman AT, Elsedfy H, Karimi M, Daar S, Wali Y, Yassin M, Soliman N, Sobti P, Al Jaouni S, El Kholly M, Fiscina B, Angastiniotis M.  $\beta$ -Thalassemia Distribution in the Old World: an Ancient Disease Seen from a Historical Standpoint. *Mediterr J Hematol Infect Dis.* 2017;9 <https://doi.org/10.4084/mjihid.2017.018>
11. Al-Obaidli A, Gerard N, Al Zadjali S, Fawzi Z, Pravin S, Pathare A, Krishnamoorthy R. A novel deletion beta thalassaemic variant in an ethnic Qatari patient. *Hemoglobin.* 2009; 33:214-219. <https://doi.org/10.1080/03630260903081398> PMID:19657835
12. Fawzi ZO, Al Hilali A, Fakhroo N, Al Bin Ali A, Al Mansour S. Distribution of Hemoglobinopathies and Thalassemias in Qatari Nationals Seen at Hamad Hospital in Qatar. *Qatar Med J.* 2003; 12: 22-24 <https://doi.org/10.5339/qmj.2003.1.11>
13. De Sanctis V, Soliman AT, Elsedfy H, Skordis N, Kattamis C, Angastiniotis M, Karimi M, Yassin MA, El Awwa A, Stoeva I, Raiola G, Galati MC, Bedair EM, Fiscina B, El Kholly M. Growth and endocrine disorders in thalassemia: The international network on endocrine complications in thalassemia (I-CET) position statement and guidelines. *Indian J Endocrinol Metab.* 2013;17:8-18. <https://doi.org/10.4103/2230-8210.107808> PMID:23776848 PMCid:PMC3659911
14. WHO Multicenter Growth Reference Study Group. WHO Child Growth Standards based on length/height, weight and age. *Acta Paediatr.* 2006; 450 (Suppl):76-85.
15. Soliman AT, Al Yafei F, Al-Naimi L, Almarri N, Sabt A, Yassin M, De Sanctis V. Longitudinal study on thyroid function in patients with thalassemia major: High incidence of central hypothyroidism by 18 years. *Indian J Endocrinol Metab.* 2013; 17:1090-1095. <https://doi.org/10.4103/2230-8210.122635> PMID:24381890 PMCid:PMC3872691
16. Puavilai G, Chanprasertyotin S, Sriprapadaeng A. Diagnostic criteria for diabetes mellitus and other categories of glucose intolerance: 1997 criteria by the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (ADA), 1998 WHO consultation criteria, and 1985 WHO criteria. *World Health Organization. Diabetes Res Clin Pract.* 1999;44:21-26. [https://doi.org/10.1016/S0168-8227\(99\)00008-X](https://doi.org/10.1016/S0168-8227(99)00008-X)
17. Bondanelli M, Ambrosio MR, Cavazzini L, Bertocchi A, Zatelli MC, Carli A, Valle D, Basaglia N, Uberti EC. Anterior pituitary function may predict functional and cognitive outcome in patients with



- traumatic brain injury undergoing rehabilitation. *J Neurotrauma*. 2007;24:1687-1697. <https://doi.org/10.1089/neu.2007.0343> PMID:18001199
18. Alberti C1, Chevenne D, Mercat I, Jossierand E, Armoogum-Boizeau P, Tichet J, Léger J. Serum concentrations of insulin-like growth factor (IGF)-1 and IGF binding protein-3 (IGFBP-3), IGF-1/IGFBP-3 ratio, and markers of bone turnover: reference values for French children and adolescents and z-score comparability with other references. *Clin Chem*. 2011;157:1424-1435.
  19. Kanbour I, Chandra P, Soliman A, De Sanctis V, Nashwan A, Abusamaan S, Moustafa A, Yassin MA. Severe liver iron concentrations (LIC) in 24 patients with  $\beta$ -thalassemia major: correlations with serum ferritin, liver enzymes, and endocrine complications. *Mediterr J Hematol Infect Dis* 2018, 10(1): e2018062, <https://doi.org/10.4084/mjihid.2018.062>
  20. Verlhac S, Morel M, Bernaudin F, Béchet S, Jung C, Vasile M. Liver iron overload assessment by MRI R2\* relaxometry in highly transfused pediatric patients: an agreement and reproducibility study. *Diagn Interv Imaging*. 2015;96:259-264. <https://doi.org/10.1016/j.diii.2014.11.021> PMID:25533496
  21. St Pierre TG, El-Beshlawy A, Elalfy M, Al Jefri A, Al Zir K, Daar S, Habr D, Kriemler-Krahn U, Taher A. Multicenter validation of spin-density projection-assisted R2-MRI for the noninvasive measurement of liver iron concentration. *Magn Reson Med*. 2014;71:2215-2223. <https://doi.org/10.1002/mrm.24854> PMID:23821350 PMCid:PMC4238736
  22. Orvieto R, Leichter I, Rachmilewitz EA, Margulies JY. Bone density, mineral content, and cortical index in patients with thalassemia major and the correlation to their bone fractures, blood transfusions, and treatment with desferrioxamine. *Calcif Tissue Int*. 1992;50: 397-399. <https://doi.org/10.1007/BF00296768> PMID:1596775
  23. Taher A, Isma'eel H, Cappellini MD. Thalassemia intermedia: revisited. *Blood Cells Mol Dis*. 2006;37:12-20. <https://doi.org/10.1016/j.bcmd.2006.04.005> PMID:16737833
  24. Fiorelli G, Fragon S, Piperno A, Battafarano N, Cappellini MD. Iron metabolism in thalassemia intermedia. *Haematologica*. 1990;75:89-95. PMID:2086386
  25. Pippard MJ, Warner GT, Callender ST, Weatherall DJ. Iron absorption and loading in  $\beta$ -thalassaemia intermedia. *Lancet*. 1979;2:819-821. [https://doi.org/10.1016/S0140-6736\(79\)92175-5](https://doi.org/10.1016/S0140-6736(79)92175-5)
  26. Celada. Iron overload in non-transfused patient with thalassemia intermedia. *Scand J Haematol* 1982, 28:169-174 PMID:7089477
  27. Shah R, Trehan A, Das R, Marwaha RK. Serum ferritin in thalassemia intermedia. *Indian J Hematol Blood Transfus*. 2013;30:281-285. <https://doi.org/10.1007/s12288-013-0267-y> PMID:25435728 PMCid:PMC4243403
  28. Musallam KM, Cappellini MD, Wood JC, Motta I, Graziadei G, Tamim H, Taher AT. Elevated liver iron concentration is a marker of increased morbidity in patients with  $\beta$  thalassemia intermedia. *Haematologica*. 2011;96:1605-1612. <https://doi.org/10.3324/haematol.2011.047852> PMID:21791471 PMCid:PMC3208677
  29. Taher A, El Rassi F, Isma'eel H, Koussa S, Inati A. Correlation of serum ferritin levels and liver iron concentration determined by R2\* MRI in patients with thalassemia intermedia. *Blood*. 2007;110:3818.
  30. Taher AT, Musallam KM, Saliba AN, Graziadei G, Cappellini MD. Hemoglobin level and morbidity in non-transfusion-dependent thalassemia. *Blood Cells Mol Dis*. 2015; 55 :108-109. <https://doi.org/10.1016/j.bcmd.2015.05.011> PMID:26142325
  31. Karamifar H, Karimi M, Amirhakimi GH, Badiei M. Endocrine function in thalassemia intermedia. *Int J Biomed Sci*. 2006;2:236-240. PMID:23674986 PMCid:PMC3614602
  32. Musallam KM, Sankaran VG, Cappellini MD, Duca L, Nathan DG, Taher AT. Fetal hemoglobin levels and morbidity in untransfused patients with  $\beta$ -thalassemia intermedia. *Blood*. 2012;119:364-367. <https://doi.org/10.1182/blood-2011-09-382408> PMID:22096240
  33. Soliman AT, De Sanctis V, Kalra S. Anemia and growth. *Indian J Endocrinol Metab*. 2014;18 (Suppl 1):S1-5. <https://doi.org/10.4103/2230-8210.145038> PMID:25538873 PMCid:PMC4266864
  34. Soliman AT, De Sanctis V, Yassin M, Adel A. Growth and Growth hormone - Insulin Like Growth Factor -I (GH-IGF-I) Axis in Chronic Anemias. *Acta Biomed*. 2017;88:101-111. PMID:28467344
  35. Soliman AT, De Sanctis V, Elalaily R, Yassin M. Insulin-like growth factor- I and factors affecting it in thalassemia major. *Indian J Endocrinol Metab*. 2015;19:245-251. <https://doi.org/10.4103/2230-8210.131750> PMID:25729686 PMCid:PMC4319264
  36. De Sanctis V, Soliman AT, Candini G, Yassin M, Raiola G, Galati MC, Elalaily R, Elsedfy H, Skordis N, Garofalo P, Anastasi S, Campisi S, Karimi M, Kattamis C, Canatan D, Kilinc Y, Sobti P, Fiscina B, El Kholy M. Insulin-like Growth Factor-1 (IGF-1): Demographic, Clinical and Laboratory Data in 120 Consecutive Adult Patients with Thalassemia Major. *Mediterr J Hematol Infect Dis*. 2014 Nov 1;6 <https://doi.org/10.4084/mjihid.2014.074>
  37. Fung EB, Xu Y, Trachtenberg F, Odame I, Kwiatkowski JL, Neufeld EJ, Thompson AA, Boudreaux J, Quinn CT, Vichinsky EP; Thalassemia Clinical Research Network. Inadequate dietary intake in patients with thalassemia. *J Acad Nutr Diet*. 2012;112:980-90. <https://doi.org/10.1016/j.jand.2012.01.017> PMID:22551675 PMCid:PMC3419338
  38. Flatau E, Resnitzky P, Kauffman N, Harpaz S, Kohn D. Iron loading and endocrine functions in nontransfused patients with beta-thalassemia intermedia or sickle-cell thalassemia. *Isr J Med Sci*. 1981;17:22-27. PMID:7461943
  39. Karimi M, Zarei T, Haghpanah S, Azarkeivan A, Kattamis C, Ladis V, Kattamis A, Kilinc Y, Daar S, Alyaarubi S, Yasseen D, Yassin M, Soliman AT, Canatan D, Obiedat M, Al-Rimawi H, Mariannis D, Christodoulides C, Christou S, Tzoulis P, De Sanctis V . Evaluation of endocrine complications in beta-thalassemia intermedia patients: A cross-sectional multicenter study. *ASH annual meeting* December 2018, Abstract 2343.
  40. Baldini M, Marcon A, Cassin R, Olivieri FM, Spinelli D, Cappellini MD, Graziadei G. Beta-thalassemia intermedia: evaluation of endocrine and bone complications. *Biomed Res Int*. 2014;2014:174581. doi: 10.1155/2014/174581. <https://doi.org/10.1155/2014/174581>
  41. Chouliaras G, Yiannoutsos CT, Berdoukas V, Ladis V. Cardiac related death in thalassemia major: time trend and risk factors in a large Greek Unit. *Eur J Haematol*. 2009;82:381-387. <https://doi.org/10.1111/j.1600-0609.2009.01218.x> PMID:19141117
  42. Taher AT, Porter J, Viprakasit V, et al. Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled study. *Blood*. 2012; 120:970-977. <https://doi.org/10.1182/blood-2012-02-412692> PMID:22589472
  43. Saliba AN, Musallam KM, Cappellini MD, et al. Serum ferritin values between 300 and 800 ng/mL in nontransfusion-dependent thalassemia: A probability curve to guide clinical decision making when MRI is unavailable. *Am J Hematol*. 2017;92:E35-E37. <https://doi.org/10.1002/ajh.24628> PMID:28052365
  44. Taher AT, Porter JB, Viprakasit V, Kattamis A, Chuncharunee S, Sutcharithan P, Siritanaratkul N, Galanello R, Karakas Z, Lawniczek T, Habr D, Ros J, Zhu Z, Cappellini MD. Deferasirox effectively reduces iron overload in non-transfusion-dependent thalassemia (NTDT) patients: 1-year extension results from the THALASSA study. *Ann Hematol*. 2013;92:1485-1493. <https://doi.org/10.1007/s00277-013-1808-z> PMID:23775581 PMCid:PMC3790249
  45. Fortin PM, Fisher SA, Madgwick KV, Trivella M, Hopewell S, Doree C, Estcourt LJ. Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia. *Cochrane Database Syst Rev*. 2018 May 8;5:CD012349. doi: 10.1002/14651858.CD012349.pub2.
  46. Yassin MA, Soliman AT, De Sanctis V, Hussein RM, Al-Okka R, Kassem N, Ghasoub R, Basha A, Nashwan AJ, Adel AM. Jadenu® Substituting Exjade® in Iron Overloaded  $\beta$ -Thalassemia Major (BTM) Patients: A Preliminary Report of the Effects on the Tolerability, Serum Ferritin Level, Liver Iron Concentration and Biochemical Profiles. *Mediterr J Hematol Infect Dis*. 2018 Nov 1;10(1):e2018064. <https://doi.org/10.4084/mjihid.2018.064>
  47. Chowdhury P, Saha M, Chowdhury D. Correlation of serum ferritin with hepatic iron overload among non-transfusion dependent beta thalassaemia with haemoglobin E disease patients from Eastern India. *J Mol Biomark Diagn*. 2015; 6: 231. doi: 10.4172/2155-9929.1000231. <https://doi.org/10.4172/2155-9929.1000231>
  48. Taher A.; Vichinsky, E.; Musallam, K.; Cappellini, M.D.; Viprakasit, V. Guidelines for the Management of Non Transfusion Dependent Thalassemia (NTDT); Thalassemia International Federation: Nicosia, Cyprus, 2013.